{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:52:46Z","timestamp":1793659966352,"version":"4.5.1"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Histone deacetylase inhibitors (HDAC inhibitors, HDACi) have garnered considerable attention due to their potential in treating various types of malignant tumors. Histone deacetylases (HDACs) not only influence chromatin structure and gene transcription by regulating histone acetylation status but also acetylate various non-histone proteins. They are widely involved in several key biological processes, such as cell cycle regulation, apoptosis induction, and immune responses. HDACi exert their effects by inhibiting HDAC activity; however, these effects are highly concentration-dependent and non-selective. HDACi inevitably disrupt both gene expression and signaling networks, leading to multi-target, non-specific biological effects. This article focuses on the immunomodulatory mechanisms of HDACi, including their role in remodeling the tumor extracellular matrix and their impact on various immune cell populations. The synergistic potential of combining HDACi with other therapeutic approaches is also discussed. This review examines the application of HDACi across different tumor types, highlighting preclinical and clinical evidence that demonstrates the multifunctionality and efficacy of HDACi. By leveraging their unique mechanism of action, HDACi opens new avenues for enhancing antitumor immunity and achieving durable therapeutic responses. Future research and clinical trials will play a crucial role in optimizing the use of HDACi, elucidating resistance mechanisms, and identifying the most effective combinations to maximize patient benefit.<\/jats:p>","DOI":"10.3389\/fonc.2025.1576781","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:10:24Z","timestamp":1750983024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiaqi","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhou","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiateng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136910","article-title":"Histone deacetylases in retinoblastoma","volume":"25","author":"Lisek","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and Malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-014-0043-2","article-title":"The histone deacetylase Hdac1 regulates inflammatory signalling in intestinal epithelial cells","volume":"11","author":"Gonneaud","year":"2014","journal-title":"J Inflammation (Lond)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.chembiol.2018.04.007","article-title":"Histone deacetylase 11 is an \u03f5-N-myristoyllysine hydrolase","volume":"25","author":"Moreno-Yruela","year":"2018","journal-title":"Cell Chem Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.10.062","article-title":"Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer","volume":"376","author":"Li","year":"2024","journal-title":"J Controlled Release"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1042\/BST20230693","article-title":"Revealing chromatin-specific functions of histone deacylases","volume":"52","author":"Moreno-Yruela","year":"2024","journal-title":"Biochem Soc Trans"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189150","article-title":"Histone deacetylase complexes: structure, regulation and function","volume":"1879","author":"Asmamaw","year":"2024","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/1568026615666150825125857","article-title":"Histone and non-histone targets of dietary deacetylase inhibitors","volume":"16","author":"Kim E","year":"2015","journal-title":"CTMC"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157947","article-title":"The role of post-translational acetylation and deacetylation of signaling proteins and transcription factors after cerebral ischemia: facts and hypotheses","volume":"22","author":"Demyanenko","year":"2021","journal-title":"IJMS"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int J Biol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.1.377","article-title":"Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation","volume":"97","author":"Chen","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273518","article-title":"The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer","volume":"17","author":"Knoche","year":"2022","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-23-10333.2002","article-title":"Histone deacetylase activity is necessary for oligodendrocyte lineage progression","volume":"22","author":"Marin-Husstege","year":"2002","journal-title":"J Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415195112","article-title":"HDAC inhibition imparts beneficial transgenerational effects in huntington\u2019s disease mice via altered DNA and histone methylation","volume":"112","author":"Jia","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13148-023-01582-x","article-title":"Peripheral blood DNA methylation and neuroanatomical responses to HDACi treatment that rescues neurological deficits in a kabuki syndrome mouse model","volume":"15","author":"Goodman","year":"2023","journal-title":"Clin Epigenet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3107","article-title":"Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI","volume":"31","author":"Zuo","year":"2014","journal-title":"Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4453","article-title":"Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in Malignant glioma","volume":"66","author":"Foltz","year":"2006","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab188","article-title":"Phase I\/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a children\u2019s oncology group report","volume":"24","author":"Su","year":"2022","journal-title":"Neuro-oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.02.001","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29229","article-title":"Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial","volume":"121","author":"Hainsworth","year":"2015","journal-title":"Cancer"},{"key":"B25","volume-title":"Livertox: Clinical and Research Information on Drug-induced Liver Injury","year":"2012"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23773","article-title":"HDAC inhibitor regulates the tumor immune microenvironment via pyroptosis in triple-negative breast cancer","volume":"63","author":"Yang","year":"2024","journal-title":"Mol Carcinog"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010054","article-title":"Role of histone deacetylase 6 and histone deacetylase 6 inhibition in colorectal cancer","volume":"16","author":"Vuleti\u0107","year":"2023","journal-title":"Pharmaceutics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.canlet.2019.07.009","article-title":"Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines","volume":"461","author":"Marampon","year":"2019","journal-title":"Cancer Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12916-022-02598-5","article-title":"Optimized dose-selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206411","article-title":"Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis","volume":"70","author":"Korfei","year":"2015","journal-title":"Thorax"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0072-3","article-title":"Suppression of TGF\u03b2-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition","volume":"118","author":"Kim","year":"2018","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7150\/thno.82535","article-title":"The HDAC10 instructs macrophage M2 program via deacetylation of STAT3 and promotes allergic airway inflammation","volume":"13","author":"Zhong","year":"2023","journal-title":"Theranostics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.73264","article-title":"TMP195 exerts antitumor effects on colorectal cancer by promoting M1 macrophages polarization","volume":"18","author":"Han","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2181","article-title":"HDACi-dependent microenvironmental normalization overcomes tumor burden\u2013induced T-cell exhaustion","volume":"29","author":"Nguyen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300475","article-title":"Histone deacetylase inhibitors directly modulate T cell gene expression and signaling and promote development of effector-exhausted T cells in murine tumors","volume":"212","author":"Ibrahim","year":"2024","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00358","article-title":"A novel liver cancer-selective histone deacetylase inhibitor is effective against hepatocellular carcinoma and induces durable responses with immunotherapy","volume":"7","author":"Wu","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1038\/ncomms7838","article-title":"Manipulation of B-cell responses with histone deacetylase inhibitors","volume":"6","author":"Waibel","year":"2015","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12967-020-02318-8","article-title":"HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines","volume":"18","author":"Iveland","year":"2020","journal-title":"J Transl Med"},{"key":"B42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-6527-4_7","article-title":"Effects of HDACi on immunological functions","volume-title":"HDAC\/HAT Function Assessment and Inhibitor Development. Methods in Molecular Biology","author":"Winkler","year":"2017"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109753","article-title":"Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway","volume":"116","author":"Zheng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac068","article-title":"Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma","volume":"209","author":"Lu","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27546","article-title":"Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway","volume":"11","author":"Idso","year":"2020","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.244","article-title":"HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells","volume":"25","author":"Song","year":"2011","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1145","article-title":"Epigenetic activation of plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AML","volume":"12","author":"Salmon","year":"2022","journal-title":"Cancer Discov"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-07065-7","article-title":"Trichostatin A inhibits dendritic cell maturation through down-regulating NF\u2014\u03ba B (p65) pathway","volume":"49","author":"Yu","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-444-63486-3.00015-3","article-title":"Targeting of ECM molecules and their metabolizing enzymes and receptors for the treatment of CNS diseases","volume-title":"Prog Brain Res","author":"Berezin","year":"2014"},{"key":"B50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.biomaterials.2014.10.017","article-title":"Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds","volume":"37","author":"Spiller","year":"2015","journal-title":"Biomaterials"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2022.988981","article-title":"Canine polarized macrophages express distinct functional and transcriptomic profiles","volume":"9","author":"Chow","year":"2022","journal-title":"Front Vet Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdsr.2019.09.001","article-title":"Immunomodulatory aspects in the progression and treatment of oral Malignancy","volume":"55","author":"Kondoh","year":"2019","journal-title":"Japanese Dental Sci Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29122881","article-title":"Efficacy of trametinib in alleviating cisplatin-induced acute kidney injury: inhibition of inflammation, oxidative stress, and tubular cell death in a mouse model","volume":"29","author":"Lee","year":"2024","journal-title":"Mol (basel Switz)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690207","article-title":"Regulatory effects of histone deacetylase inhibitors on myeloid-derived suppressor cells","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: an update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978800","article-title":"HDAC inhibitors panobinostat and romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients\u2019 T-cells","volume":"13","author":"Schnell","year":"2022","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0195","article-title":"Isoform-selective versus nonselective histone deacetylase inhibitors in HIV latency reversal","volume":"38","author":"Boateng","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-292003","article-title":"Histone\/protein deacetylases and T-cell immune responses","volume":"119","author":"Akimova","year":"2012","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.12.006","article-title":"B-cell metabolic remodeling and cancer","volume":"4","author":"FranChina","year":"2018","journal-title":"Trends Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.236711","article-title":"An HDAC6 inhibitor confers protection and selectively inhibits B-cell infiltration in DSS-induced colitis in mice","volume":"360","author":"Do","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41467-023-44540-0","article-title":"MCT1-governed pyruvate metabolism is essential for antibody class-switch recombination through H3K27 acetylation","volume":"15","author":"Chi","year":"2024","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0711339","article-title":"Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression","volume":"91","author":"Rossi","year":"2011","journal-title":"J Leukocyte Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159283","article-title":"HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity","volume":"132","author":"Nguyen","year":"2022","journal-title":"J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cellimm.2017.02.006","article-title":"Histone deacetylase inhibitors suppress immature dendritic cell\u2019s migration by regulating CC chemokine receptor 1 expression","volume":"316","author":"Kim","year":"2017","journal-title":"Cell Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.09.008","article-title":"The B7x immune checkpoint pathway: from discovery to clinical trial","volume":"40","author":"John","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7150\/thno.69444","article-title":"HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Theranostics"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006857","article-title":"Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia","volume":"11","author":"Wen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3748\/wjg.v26.i6.598","article-title":"Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer","volume":"26","author":"Amnekar","year":"2020","journal-title":"WJG"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-008086","article-title":"Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor","volume":"108","author":"Sanchez-Gonzalez","year":"2006","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3738","article-title":"HDAC6 plays a noncanonical role in the regulation of antitumor immune responses, dissemination, and invasiveness of breast cancer","volume":"80","author":"Banik","year":"2020","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i18.1934","article-title":"Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases","volume":"28","author":"Sim","year":"2022","journal-title":"WJG"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","article-title":"Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70725","article-title":"A phase I\/IB, open label, dose finding study to evaluate safety, pharmacodynamics and efficacy of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial carcinoma","volume":"14","author":"Pili","year":"2025","journal-title":"Cancer Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12885-020-07008-8","article-title":"INFORM2 NivEnt: the first trial of the INFORM2 biomarker driven phase I\/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk Malignancies","volume":"20","author":"van Tilburg","year":"2020","journal-title":"BMC Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.01.013","article-title":"Mocetinostat in combination with durvalumab for patients with advanced NSCLC: results from a phase I\/II study","volume":"24","author":"Johnson","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","article-title":"Combining epigenetic and immune therapy to overcome cancer resistance","volume":"65","author":"Gomez","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1170207","article-title":"HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma","volume":"14","author":"Shen","year":"2023","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2786","article-title":"Rational combinations using HDAC inhibitors","volume":"15","author":"Bots","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Akbarali","year":"2022","journal-title":"Adv Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115197","article-title":"EGCG adjuvant chemotherapy: Current status and future perspectives","volume":"250","author":"Wang","year":"2023","journal-title":"Eur J Medicinal Chem"},{"key":"B87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","article-title":"Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)","volume":"15","author":"Lu","year":"2023","journal-title":"Clin Epigenet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0154-8","article-title":"Combining carfilzomib and panobinostat to treat relapsed\/refractory multiple myeloma: results of a multiple myeloma research consortium phase I study","volume":"9","author":"Kaufman","year":"2019","journal-title":"Blood Cancer J"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00728-y","article-title":"Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma","volume":"43","author":"Zhou","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1215","article-title":"Safety and efficacy of vorinostat plus sirolimus or everolimus in patients with relapsed refractory hodgkin lymphoma","volume":"26","author":"Janku","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13148-020-00948-9","article-title":"Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2021.1983584","article-title":"Phase II study of single-agent and combination everolimus and panobinostat in relapsed or refractory diffuse large B-cell lymphoma","volume":"39","author":"Islam","year":"2021","journal-title":"Cancer Invest"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4516-x","article-title":"Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer","volume":"167","author":"Luu","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/ib study of pembrolizumab plus vorinostat in advanced\/metastatic non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9411","article-title":"Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non\u2013small-cell lung cancer who progressed on prior chemotherapy","volume":"30","author":"Witta","year":"2012","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-021-00213-6","article-title":"Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma","volume":"10","author":"Okabe","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040475","article-title":"HDAC inhibitors exert anti-myeloma effects through multiple modes of action","volume":"11","author":"Imai","year":"2019","journal-title":"Cancers"},{"key":"B101","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bjh.16160","article-title":"Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in hodgkin and T-cell lymphoma","volume":"188","author":"Passero","year":"2020","journal-title":"Br J Haematol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.02.010","article-title":"Nrf2-miR-129-3p-mTOR axis controls an miRNA regulatory network involved in HDACi-induced autophagy","volume":"27","author":"Sun","year":"2019","journal-title":"Mol Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2219392","article-title":"Advances in hodgkin\u2019s lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors","volume":"24","author":"Ho","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15649","article-title":"Synergistic interactions between PLK1 and HDAC inhibitors in non-hodgkin\u2019s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms","volume":"8","author":"Nguyen","year":"2017","journal-title":"Oncotarget"},{"key":"B105","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-022-01221-6","article-title":"Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.11.008","article-title":"HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL","volume":"147","author":"Bian","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105396","article-title":"HDAC\/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway","volume":"117","author":"Cao","year":"2021","journal-title":"Bioorg Chem"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00383-5","article-title":"Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia","volume":"12","author":"Gu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106487","article-title":"Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors","volume":"185","author":"Chen","year":"2022","journal-title":"Pharmacol Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1353077","article-title":"Entinostat for the treatment of breast cancer","volume":"26","author":"Trapani","year":"2017","journal-title":"Expert Opin Invest Drugs"},{"key":"B113","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.1038\/s41467-023-42178-6","article-title":"Inhibiting stromal Class I HDACs curbs pancreatic cancer progression","volume":"14","author":"Liang","year":"2023","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28588","article-title":"Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: implications for novel therapy","volume":"15","author":"Valdez","year":"2024","journal-title":"Oncotarget"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01957","article-title":"Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer","volume":"62","author":"Shouksmith","year":"2019","journal-title":"J Med Chem"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.07.003","article-title":"Histone deacetylase inhibitors inhibit cervical cancer growth through parkin acetylation-mediated mitophagy","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174399","article-title":"Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway","volume":"908","author":"Pan","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10735-022-10105-6","article-title":"4SC-202 exerts an anti-tumor effect in cervical cancer by targeting PRLR signaling pathway","volume":"53","author":"Zhang","year":"2022","journal-title":"J Mol Histol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2023.09.019","article-title":"Epidemiology and survival outcomes of colorectal mixed neuroendocrine\u2013non-neuroendocrine neoplasms and neuroendocrine carcinoma","volume":"175","author":"Suraju","year":"2024","journal-title":"Surgery"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143650","article-title":"NOXA accentuates apoptosis induction by a novel histone deacetylase inhibitor","volume":"15","author":"Ashry","year":"2023","journal-title":"Cancers"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06205-0","article-title":"Targeting the E2F1\/Rb\/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth","volume":"14","author":"Duan","year":"2023","journal-title":"Cell Death Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300655","article-title":"Uracil- and pyridine-containing HDAC inhibitors displayed cytotoxicity in colorectal and glioblastoma cancer stem cells","volume":"19","author":"Fiorentino","year":"2024","journal-title":"ChemMedChem"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115879","article-title":"Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency","volume":"262","author":"Pan","year":"2023","journal-title":"Eur J Medicinal Chem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116634","article-title":"Biological function and small molecule inhibitors of histone deacetylase 11","volume":"276","author":"Jia","year":"2024","journal-title":"Eur J Medicinal Chem"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116696","article-title":"Overview of class I HDAC modulators: Inhibitors and degraders","volume":"276","author":"Huang","year":"2024","journal-title":"Eur J Medicinal Chem"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1576781\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:10:25Z","timestamp":1750983025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1576781\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":125,"alternative-id":["10.3389\/fonc.2025.1576781"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1576781","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"1576781"}}